Primary cutaneous NK/T-cell lymphoma, nasal type and CD56-positive peripheral T-cell lymphoma: a cellular lineage and clinicopathologic study of 60 patients from Asia.

Am J Surg Pathol

*Department of Pathology, Okayama University Graduate School of Medicine Medical School, Okayama ***Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan †Department of Pathology, Samsung Medical Center ∥∥Department of Pathology, Samsung Medical Center and Sungkyunkwan University, Seoul, Korea ‡Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand Departments of §Pathology §§Medicine, Queen Mary Hospital, Hong Kong SAR, China ∥Department of Pathology, Singapore General Hospital Departments of **Pathology ##Haematology-Oncology, National University Health System ††Cancer Science Institute of Singapore, National University of Singapore, Singapore ¶Department of Pathology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan †††Department of Pathology, Chi-Mei Medical Center, Tainan, Taipei Medical University and National Taiwan University ¶¶Department of Dermatology, National Taiwan University Hospital, Taipei #Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital ‡‡Department of Pathology, Kaohsiung Medical University Hospital and College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

Published: January 2015

Primary cutaneous, extranodal natural killer/T-cell lymphoma, nasal type (PC-ENKTL), is a rare Epstein-Barr virus (EBV)-associated neoplasm with poorly defined clinicopathologic features. We performed a multinational retrospective study of PC-ENKTL and CD56-positive EBV-negative peripheral T-cell lymphoma (PC-CD56+PTCL) in Asia in an attempt to elucidate their clinicopathologic features. Using immunohistochemistry for T-cell receptors (TCRs), in situ hybridization for EBV, and TCR gene rearrangement, we classified 60 tumors into 51 with PC-ENKTL (20 of NK-cell, 17 T-cell, and 14 indeterminate lineages) and 9 with PC-CD56+PTCL. Tumors of T-cell origin accounted for 46% of PC-ENKTLs with half of these cases being TCR-silent. As compared with T-lineage tumors, PC-ENKTLs of NK-cell lineage had more frequent involvement of regional lymph nodes and more frequently CD8-negative and CD56-positive. Cases of PC-ENKTL showed more frequent tumor necrosis, younger age, and a higher frequency of CD16 and CD30 expression than cases of PC-CD56+PTCL. CD56-positive T-lineage PC-ENKTL tumors (n=8) had more localized disease in the TNM (tumor-node-metastasis) staging and were more often of γδ T-cell origin compared with cases of PC-CD56+PTCL (n=9). PC-ENKTLs and PC-CD56+PTCLs were equally aggressive, with a 5-year overall survival rate of 25%. Tumor necrosis and CD16 expression may serve as useful surrogates for differentiating PC-ENKTL from PC-CD56+PTCL. A single lesion, an elevated lactate dehydrogenase level, and the presence of B symptoms were independent poor prognostic factors for PC-ENKTL in multivariate analysis. Further studies with more cases are warranted to delineate the clinicopathologic features and significance of EBV in these rare lymphomas.

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000312DOI Listing

Publication Analysis

Top Keywords

clinicopathologic features
12
primary cutaneous
8
lymphoma nasal
8
nasal type
8
peripheral t-cell
8
t-cell lymphoma
8
t-cell origin
8
tumor necrosis
8
cases pc-cd56+ptcl
8
pc-enktl
7

Similar Publications

Background And Objectives: Breast cancers (BCs) of patients with paraneoplastic neurologic syndromes and anti-Yo antibodies (Yo-PNS) overexpress human epidermal growth factor receptor 2 (HER2) and display genetic alterations and overexpression of the Yo-onconeural antigens. They are infiltrated by an unusual proportion of B cells. We investigated whether these features were also observed in patients with PNS and anti-Ri antibodies (Ri-PNS).

View Article and Find Full Text PDF

Nanosize Non-Viral Gene Therapy Reverses Senescence Reprograming Driven by PBRM1 Deficiency to Suppress iCCA Progression.

Adv Sci (Weinh)

January 2025

Department of Hepatic Surgery, Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.

Polybromo-1 (PBRM1) serves as a crucial regulator of gene transcription in various tumors, including intrahepatic cholangiocarcinoma (iCCA). However, the exact role of PBRM1 in iCCA and the mechanism by which it regulates downstream target genes remain unclear. This research has revealed that PBRM1 is significantly downregulated in iCCA tissues, and this reduced expression is linked to aggressive clinicopathological features and a poor prognosis.

View Article and Find Full Text PDF

Background: The aim of this study was to assess the clinicopathological features of lip lesions diagnosed in a single Oral Pathology service in Brazil.

Material And Methods: It was a cross-sectional study based on secondary data. Between 2000 and 2019, all lip lesions diagnosed in an Oral Pathology service in Brazil were analyzed.

View Article and Find Full Text PDF

PAR2 promotes malignancy in lung adenocarcinoma.

Am J Transl Res

December 2024

Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University Tianjin 300070, China.

Proteinase-activated receptor-2 (PAR2) is closely linked to tumor malignancy, but its biological role in cancer remains underexplored. In this study, we assessed PAR2 expression in lung adenocarcinoma (LUAD) and normal lung tissues, analyzed associations between clinicopathological features and survival rates, and confirmed that PAR2 promotes apoptosis resistance and reduces cisplatin-induced cytotoxicity in lung cancer cells. Using TCGA datasets, western blotting, qPCR, and immunohistochemistry (IHC), we observed a significant increase in PAR2 levels in LUAD samples compared to normal tissues (P<0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!